A bifurcated proteoglycan binding small molecule carrier for siRNA delivery

Chemical Biology and Drug Design

Volumn 84, Issue 1, 2014, Pages 24-35

  Gooding, Matt ^a,c   Adigbli, Derick ^b   Edith Chan, A W ^a   Melander, Roberta J ^a,d   MacRobert, Alexander J ^b   Selwood, David L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

biophysical chemistry; carbohydrate; chemical biology; lipid; nucleic acid; RNAi and antisense techniques

Indexed keywords

HEPARIN; LIPOFECTAMINE; POLYARGININE; PROTEOGLYCAN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; DRUG CARRIER; HEPARIN PROTEOGLYCAN; LIPID; MESSENGER RNA;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ANALOGS AND DERIVATIVES; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; PROCEDURES; RNA INTERFERENCE;

CELL LINE; DRUG CARRIERS; HEPARIN; HUMANS; LIPIDS; MODELS, MOLECULAR; PROTEOGLYCANS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84902662519     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12295     Document Type: Article

References (33)

1. Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M., et al,. (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther; 18: 442-446.
2. Barakat M.R., Kaiser P., (2009) VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs; 18: 637-646.
3. Gooding M., Browne L.P., Quinteiro F.M., Selwood D.L., (2012) siRNA delivery: from lipids to cell-penetrating peptides and their mimics. Chem Biol Drug Des; 80: 787-809.
4. Guo J., Fisher K.A., Darcy R., Cryan J.F., O'Driscoll C., (2010) Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol BioSyst; 6: 1143-1161.
5. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al,. (2006) RNAi-mediated gene silencing in non-human primates. Nature; 441: 111-114.
6. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al,. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol; 28: 172-176.
7. Vaishnaw A.K., Cervantes A., Alsina M., Tabernero J., Infante J.R., LoRusso P., et al,. (2011) RNAi in humans: phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumours with liver involvment. Nucl Acid Ther; 21: A44-A.
8. Coelho T., Suhr O.B., Adams D., Lozeron P., Hawkins P., Mant T., et al,. (2011) Interim clinical update for ALN-TTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloidosis. J Peripher Nerv Syst; 16: S25-S26.
9. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al,. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature; 464: 1067-1070.
10. Davis M.E., (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm; 6: 659-668.
11. Veronese F.M., Pasut G., (2005) PEGylation, successful approach to drug delivery. Drug Discov Today; 10: 1451-1458.
12. Meister G., Tuschl T., (2004) Mechanisms of gene silencing by double-stranded RNA. Nature; 431: 343-349.
13. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G., (2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release; 129: 107-116.
14. Li W., Szoka F.C., (2007) Lipid-based nanoparticles for nucleic acid delivery. Pharm Res; 24: 438-449.
15. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J., et al,. (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem; 18: 1450-1459.
16. Won Y.-W., Kim H.A., Lee M., Kim Y.-H., (2010) Reducible poly(oligo-D-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol Ther; 18: 734-742.
17. Crombez L., Morris M.C., Dufort S., Aldrian-Herrada G., Nguyen Q., McMaster G., et al,. (2009) Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res; 37: 4559-4569.
18. Nakase I., Tadokoro A., Kawabata N., Takeuchi T., Katoh H., Hiramoto K., et al,. (2006) Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis†. Biochemistry; 46: 492-501.
19. Ziegler A., (2008) Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev; 60: 580-597.
20. Fuchs S.M., Raines R.T., (2004) Pathway for polyarginine entry into mammalian cells†. Biochemistry; 43: 2438-2444.
21. Rullo A., Qian J., Nitz M., (2011) Peptide-glycosaminoglycan cluster formation involving cell penetrating peptides. Biopolymers; 95: 722-731.
22. Gooding M., Tudzarova S., Worthington R.J., Kingsbury S.R., Rebstock A.S., Dube H., et al,. (2012) Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNA. Chem Biol Drug Des; 79: 9-21.
23. Okuyama M., Laman H., Kingsbury S.R., Visintin C., Leo E., Eward K.L., et al,. (2007) Small-molecule mimics of an [alpha]-helix for efficient transport of proteins into cells. Nat Methods; 4: 153-159.
24. Rebstock A.S., Visintin C., Leo E., Posada C.G., Kingsbury S.R., Williams G.H., et al,. (2008) Modular assembly using sequential palladium coupling gives easy access to the SMoC class of cellular transporters. ChemBioChem; 9: 1787-1796.
25. Krieger E., Koraimann G., Vriend G., (2002) Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins; 47: 393-402.
26. Ziegler A., Seelig J., (2008) Binding and clustering of glycosaminoglycans: a common property of mono- and multivalent cell-penetrating compounds. Biophys J; 94: 2142-2149.
27. Simon M.J., Gao S., Kang W.H., Banta S., Morrison B., (2009) TAT-mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expression. Biotechnol Bioeng; 104: 10-19.
28. Patel L.N., Zaro J.L., Shen W.C., (2007) Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res; 24: 1977-1992.
29. Gerbal-chaloin S., Gondeau C., Aldrian-herrada G., Heitz F., Gauthier-rouvière C., Divita G., (2007) First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network remodelling. Biol Cell; 99: 223-238.
30. Couchman J.R., (2003) Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol; 4: 926-938.
31. Gump J.M., June R.K., Dowdy S.F., (2010) Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J Biol Chem; 285: 1500-1507.
32. Lépinoux-Chambaud C., Eyer J., (2013) The NFL-TBS.40-63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis. Int J Pharm; 454: 738-747.
33. Verdurmen W.P.R., Wallbrecher R., Schmidt S., Eilander J., Bovee-Geurts P., Fanghänel S., et al,. (2013) Cell surface clustering of heparan sulfate proteoglycans by amphipathic cell-penetrating peptides does not contribute to uptake. J Control Release; 170: 83-91.